AG真人官方

STOCK TITAN

[144] Apellis Pharmaceuticals, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

On July 14, 2025, Robert M. Jenkins, Executive VP & COO of Essential Properties AG真人官方ty Trust (EPRT), automatically acquired 84 common shares at $0 under a dividend-equivalent adjustment to performance-based RSUs granted in 2022. The award, which will vest on December 31, 2025, raises his direct holding to 35,367 shares. No sales or derivative transactions were reported, and the filing contains no cash consideration or new option grants.

Il 14 luglio 2025, Robert M. Jenkins, Vicepresidente Esecutivo e COO di Essential Properties AG真人官方ty Trust (EPRT), ha acquisito automaticamente 84 azioni ordinarie a 0 $ grazie a un adeguamento equivalente al dividendo relativo a RSU basate sulle performance assegnate nel 2022. Il premio, che maturer脿 il 31 dicembre 2025, porta la sua partecipazione diretta a 35.367 azioni. Non sono state segnalate vendite o operazioni derivati, e il deposito non contiene alcun corrispettivo in denaro n茅 nuove concessioni di opzioni.

El 14 de julio de 2025, Robert M. Jenkins, Vicepresidente Ejecutivo y COO de Essential Properties AG真人官方ty Trust (EPRT), adquiri贸 autom谩ticamente 84 acciones comunes a $0 mediante un ajuste equivalente a dividendos sobre RSU basadas en desempe帽o otorgadas en 2022. La adjudicaci贸n, que se consolidar谩 el 31 de diciembre de 2025, eleva su participaci贸n directa a 35,367 acciones. No se reportaron ventas ni transacciones derivadas, y el informe no contiene compensaci贸n en efectivo ni nuevas concesiones de opciones.

2025雲� 7鞗� 14鞚�, Essential Properties AG真人官方ty Trust(EPRT)鞚� 斓滉碃鞖挫榿毂呾瀯鞛�(COO) 瓴� 攵靷灔鞚� Robert M. Jenkins臧 2022雲勳棎 攵鞐悳 靹标臣 旮半皹 RSU鞐� 雽頃� 氚半嫻旮� 靸侂嫻 臁办爼鞙茧 84欤� 氤错喌欤�毳� 0雼煬鞐� 鞛愲彊 旆摑頄堨姷雼堧嫟. 鞚� 氤挫儊鞚 2025雲� 12鞗� 31鞚�鞐� 頇曥爼霅橂┌, 攴胳潣 歆侅爲 氤挫湢 欤检嫕鞚 35,367欤�搿� 歃濌皜頃╇媹雼�. 毵る弰雮� 韺岇儩靸來拡 瓯半灅電� 氤搓碃霅橃 鞎婌晿鞙茧┌, 鞝滌稖 靹滊鞐愲姅 順勱笀 氤挫儊鞚措倶 鞁犼窚 鞓奠厴 攵鞐皜 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟.

Le 14 juillet 2025, Robert M. Jenkins, vice-pr茅sident ex茅cutif et COO d'Essential Properties AG真人官方ty Trust (EPRT), a automatiquement acquis 84 actions ordinaires0 $ dans le cadre d'un ajustement 茅quivalent au dividende sur des RSU bas茅es sur la performance attribu茅es en 2022. Cette attribution, qui sera acquise le 31 d茅cembre 2025, porte sa d茅tention directe 脿 35 367 actions. Aucune vente ni transaction d茅riv茅e n'a 茅t茅 rapport茅e, et le d茅p么t ne contient aucune contrepartie en esp猫ces ni nouvelle attribution d'options.

Am 14. Juli 2025 erwarb Robert M. Jenkins, Executive VP & COO von Essential Properties AG真人官方ty Trust (EPRT), automatisch 84 Stammaktien zu 0 $ im Rahmen einer dividenden盲quivalenten Anpassung von leistungsbasierten RSUs, die 2022 gew盲hrt wurden. Die Zuteilung, die am 31. Dezember 2025 f盲llig wird, erh枚ht seinen direkten Bestand auf 35.367 Aktien. Es wurden keine Verk盲ufe oder Derivatgesch盲fte gemeldet, und die Meldung enth盲lt weder Barverg眉tungen noch neue Optionszuteilungen.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Immaterial insider buy linked to dividend equivalents; neutral market signal.

The 84-share increase is purely mechanical, reflecting the RSU plan鈥檚 dividend-equivalent feature rather than discretionary purchasing. Total ownership moved from 35,283 to 35,367 shares, a 0.24% change鈥攚ell below any threshold likely to influence valuation or sentiment. Because no open-market cash was deployed and vesting remains contingent on 2022 performance metrics, I view the event as non-impactful to EPRT鈥檚 capital structure or float.

TL;DR: Routine Form 4; consistent with standard equity incentive policies.

The transaction discloses compliance with Section 16 reporting and highlights EPRT鈥檚 use of dividend-protected performance RSUs鈥攁 common REIT practice to align executives with shareholders. No red flags emerge: the adjustment is formulaic, the power of attorney is on file, and filing timeliness is within two days. Governance risk unchanged.

Il 14 luglio 2025, Robert M. Jenkins, Vicepresidente Esecutivo e COO di Essential Properties AG真人官方ty Trust (EPRT), ha acquisito automaticamente 84 azioni ordinarie a 0 $ grazie a un adeguamento equivalente al dividendo relativo a RSU basate sulle performance assegnate nel 2022. Il premio, che maturer脿 il 31 dicembre 2025, porta la sua partecipazione diretta a 35.367 azioni. Non sono state segnalate vendite o operazioni derivati, e il deposito non contiene alcun corrispettivo in denaro n茅 nuove concessioni di opzioni.

El 14 de julio de 2025, Robert M. Jenkins, Vicepresidente Ejecutivo y COO de Essential Properties AG真人官方ty Trust (EPRT), adquiri贸 autom谩ticamente 84 acciones comunes a $0 mediante un ajuste equivalente a dividendos sobre RSU basadas en desempe帽o otorgadas en 2022. La adjudicaci贸n, que se consolidar谩 el 31 de diciembre de 2025, eleva su participaci贸n directa a 35,367 acciones. No se reportaron ventas ni transacciones derivadas, y el informe no contiene compensaci贸n en efectivo ni nuevas concesiones de opciones.

2025雲� 7鞗� 14鞚�, Essential Properties AG真人官方ty Trust(EPRT)鞚� 斓滉碃鞖挫榿毂呾瀯鞛�(COO) 瓴� 攵靷灔鞚� Robert M. Jenkins臧 2022雲勳棎 攵鞐悳 靹标臣 旮半皹 RSU鞐� 雽頃� 氚半嫻旮� 靸侂嫻 臁办爼鞙茧 84欤� 氤错喌欤�毳� 0雼煬鞐� 鞛愲彊 旆摑頄堨姷雼堧嫟. 鞚� 氤挫儊鞚 2025雲� 12鞗� 31鞚�鞐� 頇曥爼霅橂┌, 攴胳潣 歆侅爲 氤挫湢 欤检嫕鞚 35,367欤�搿� 歃濌皜頃╇媹雼�. 毵る弰雮� 韺岇儩靸來拡 瓯半灅電� 氤搓碃霅橃 鞎婌晿鞙茧┌, 鞝滌稖 靹滊鞐愲姅 順勱笀 氤挫儊鞚措倶 鞁犼窚 鞓奠厴 攵鞐皜 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟.

Le 14 juillet 2025, Robert M. Jenkins, vice-pr茅sident ex茅cutif et COO d'Essential Properties AG真人官方ty Trust (EPRT), a automatiquement acquis 84 actions ordinaires0 $ dans le cadre d'un ajustement 茅quivalent au dividende sur des RSU bas茅es sur la performance attribu茅es en 2022. Cette attribution, qui sera acquise le 31 d茅cembre 2025, porte sa d茅tention directe 脿 35 367 actions. Aucune vente ni transaction d茅riv茅e n'a 茅t茅 rapport茅e, et le d茅p么t ne contient aucune contrepartie en esp猫ces ni nouvelle attribution d'options.

Am 14. Juli 2025 erwarb Robert M. Jenkins, Executive VP & COO von Essential Properties AG真人官方ty Trust (EPRT), automatisch 84 Stammaktien zu 0 $ im Rahmen einer dividenden盲quivalenten Anpassung von leistungsbasierten RSUs, die 2022 gew盲hrt wurden. Die Zuteilung, die am 31. Dezember 2025 f盲llig wird, erh枚ht seinen direkten Bestand auf 35.367 Aktien. Es wurden keine Verk盲ufe oder Derivatgesch盲fte gemeldet, und die Meldung enth盲lt weder Barverg眉tungen noch neue Optionszuteilungen.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

How many EPRT shares did Robert M. Jenkins acquire on July 14, 2025?

He received 84 common shares via an automatic RSU dividend-equivalent adjustment.

What is Robert M. Jenkins鈥檚 total direct ownership after the transaction?

Following the adjustment, he directly owns 35,367 EPRT shares.

Was cash paid for the newly acquired shares?

No. The shares were issued at $0 cost as part of the RSU plan.

When will the related RSUs vest?

The performance-based RSUs are scheduled to vest on December 31, 2025.

Did the filing report any share sales by the executive?

No. The Form 4 lists only an acquisition; there were no dispositions or derivative exercises.
Apellis Pharmace

NASDAQ:APLS

APLS Rankings

APLS Latest News

APLS Latest SEC Filings

APLS Stock Data

2.46B
106.64M
13.86%
103.5%
16.58%
Biotechnology
Pharmaceutical Preparations
United States
WALTHAM